Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: The role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1α expression

Journal of Neurosurgery

Volumn 100, Issue 3, 2004, Pages 488-497

  Jensen, Randy L ^a   Gillespie, David ^b   House, Paul ^b   Layfield, Lester ^b   Shelton, Clough ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Endolymphatic sac; Hypoxia inducible factor; Von Hippel Lindau disease

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADULT; ANGIOGENESIS; ARTICLE; CASE REPORT; CELL METABOLISM; DISEASE ASSOCIATION; EAR TUMOR; ENDOLYMPHATIC SAC; ENDOLYMPHATIC SAC TUMOR; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HEMANGIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING;

EID: 1442282495     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2004.100.3.0488     Document Type: Article

References (88)

1. Al-Anazi AR, Holliday W, Sheikh B, et al: Extraosseous endolymphatic sac low-grade adenocarcinoma mimicking posterior fossa meningiomas. J Neurosurg 95:893-896, 2001
2. Bender BU, Gutsche M, Glasker S, et al: Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85:4568-4574, 2000
3. Bradley JF, Collins DL, Schimke RN, et al: Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene. Am J Med Genet 87:163-167, 1999
4. Brahimi-Horn C, Berra E, Pouyssegur J: Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 11:S32-S36, 2001
5. Chen F, Kishida T, Duh FM, et al: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55:4804-4807, 1995
6. Chen F, Kishida T, Yao M, et al: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66-75, 1995
7. Cho S, Choi YJ, Kim JM, et al: Binding and regulation of HIF-1α by a subunit of the proteasome complex PSMA7. FEBS Lett 498:62-66, 2001
8. Clifford SC, Cockman ME, Smallwood AC, et al: Contrasting effects of HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10:1029-1038, 2001
9. Clifford SC, Prowse AH, Affara NA, et al: Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumorigenesis. Gene Chromosomes Cancer 22:200-209, 1998
10. Cockman ME, Masson N, Mole DR, et al: Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741, 2000
11. Dannenberg H, De Krijger RR, van der Harst E, et al: Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int J Cancer 105:190-195, 2003
12. Davidowitz EJ, Schoenfeld AR, Burk RD: VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 21: 865-874, 2001
13. Delisle MB, Uro E, Rouquette I, et al: Papillary neoplasm of the endolymphatic sac in a patient with von Hippel-Lindau disease. J Clin Pathol 47:959-961, 1994
14. Ellsworth DL, Shriver CD, Ellsworth RE, et al: Laser capture microdissection of paraffin-embedded tissues. Biotechniques 34: 42-46, 2003
15. Elson DA, Thurston G, Huang LE, et al: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev 15:2520-2532, 2001
16. Fend F, Specht K, Kremer M, et al: Laser capture microdissection in pathology. Methods Enzymol 356:196-206, 2002
17. Foster K, Prowse A, van den Berg A, et al: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169-2173, 1994
18. Friedrich CA: Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 10:763-767, 2001
19. Friedrich CA: Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer 86 (Suppl 11):2478-2482, 1999
20. Gaffey MJ, Mills SE, Boyd JC: Aggressive papillary tumor of middle ear/temporal bone and adnexal papillary cystadenoma. Manifestations of von Hippel-Lindau disease. Am J Surg Pathol 18:1254-1260, 1994
21. Gaffey MJ, Mills SE, Fechner RE, et al: Aggressive papillary middle-ear tumor. A clinicopathologic entity distinct from middle-ear adenoma. Am J Surg Pathol 12:790-797, 1988
22. Gijtenbeek JMM, Jacobs B, Sprenger SHE, et al: Analysis of von Hippel-Lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg 97:977-982, 2002
23. Glasscock ME III, McKennon KX, Levine SC, et al: Primary adenocarcinoma of the middle ear and temporal bone. Arch Otolaryngol Head Neck Surg 113:822-824, 1987
24. Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90, 1994
25. Gnarra JR, Zhou S, Merrill MJ, et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of VHL tumor suppressor gene. Proc Natl Acad Sci USA 93: 10589-10594, 1996
26. Governale LS, Vortmeyer AO, Zhuang Z, et al: Fibrous meningioma in a patient with von Hippel-Lindau disease: a genetic analysis. J Neurosurg 95:1045-1049, 2001
27. Hamazaki S, Yoshida M, Yao M, et al: Mutation of von Hippel-Lindau tumor suppressor gene in a sporadic endolymphatic sac tumor. Hum Pathol 32:1272-1276, 2001
28. Hassard AD, Boudreau SF, Cron CC: Adenoma of the endolymphatic sac. J Otolaryngol 13:213-216, 1984
29. Heffner DK: Low-grade adenocarcinoma of probably endolymphatic sac origin. A clinicopathologic study of 20 cases. Cancer 64:2292-2302, 1989
30. Herman JG, Latif F, Weng Y, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704, 1994
31. Hoffman MA, Ohh M, Yang H, et al: von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10:1019-1027, 2001
32. Hofstra RM, Stelwagen T, Stulp RP, et al: Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 81:2881-2884, 1996
33. Hyams VJ, Micheals L: Benign adenomatous neoplasm (adenoma) of the middle ear. Clin Otolaryngol 1:17-26, 1976
34. Iliopoulos O, Kibel A, Gray S, et al: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1:822-826, 1995
35. Iliopoulos O, Levy AP, Jiang C, et al: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93:10595-10599, 1996
36. Ivan M, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev 11:27-34, 2001
37. Ivan M, Kondo K, Yang H, et al: HIF-α targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292:464-468, 2001
38. Iwai K, Yamanaka K, Kamura T, et al: Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96: 12436-12441, 1999
39. Jaakkola P, Mole DR, Tian YM, et al: Targeting of HIFα to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468-472, 2001
40. Jiang BH, Rue E, Wang GL, et al: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271:17771-17778, 1996
41. Kaelin WG Jr: Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:673-682, 2002
42. Kaelin WG Jr, Maher ER: The VHL tumour-suppressor gene paradigm. Trends Genet 14:423-426, 1998
43. Kamura T, Koepp DM, Conrad MN, et al: Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-661, 1999
44. Kawahara N, Kume H, Ueki K, et al: VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease. Neurology 53:208-210, 1999
45. Kempermann G, Neumann HPH, Scheremet R, et al: Deafness due to bilateral endolympathic sac tumours in a case of von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 61: 318-320, 1996
46. Kempermann G, Neumann HPH, Volk B: Endolympathic sac tumours. Histopathology 33:2-10, 1998
47. Kondo K, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 264:117-125, 2001
48. Kondo K, Kico J, Nakamura E, et al: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246, 2002
49. Krieg M, Haas R, Brauch H, et al: Up-regulation of hypoxia inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5443, 2000
50. Lando D, Peet DJ, Whelan DA, et al: Asparagine hydroxylation of the HIF transactivation domain, a hypoxic switch. Science 295: 858-861, 2002
51. Latif F, Tory K, Gnarra J, et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-1320, 1993
52. Lieubeau-Teillet B, Rak J, Jothy S, et al: von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58:4957-4962, 1998
53. Lubensky IA, Gnarra JR, Bertheau P, et al: Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149: 2089-2094, 1996
54. Maher ER, Kaelin WG Jr: Von Hippel-Lindau disease. Medicine 76:381-391, 1997
55. Mandriota SJ, Turner KJ, Davies DR, et al: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468, 2002
56. Manski TJ, Heffner DK, Glenn GM, et al: Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 277:1461-1466, 1997
57. Maranchie JK, Vasselli JR, Riss J, et al: The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255, 2002
58. Maxwell PH, Wiesener MS, Chang GW, et al: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
59. Megerian CA, McKenna MJ, Nuss RC, et al: Endolymphatic sac tumors: histopathologic confirmation, clinical characterization, and implication in von Hippel-Lindau disease. Laryngoscope 105:801-808, 1995
60. Neumann H, Bausch B, McWhinney SR, et al: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346: 1459-1466, 2002
61. Neumann HP, Bender BU: Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 243:541-545, 1998
62. Neumann HP, Berger DP, Sigmund G, et al: Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329:1531-1538, 1993
63. Ohh M, Park CW, Ivan M, et al: Ubiquitination of hypoxia-inducible factor requires direct binding to the B-domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427, 2000
64. Pallanch JF, Weiland LH, McDonald TJ, et al: Adenocarcinoma and adenoma of the middle ear. Laryngoscope 92:47-54, 1982
65. Pause A, Peterson B, Schaffar G, et al: Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci USA 96:9533-9538, 1999
66. Poe DS, Tarlov EG, Thomas CB, et al: Aggressive papillary tumors of temporal bone. Otolaryngol Head Neck Surg 108: 80-86, 1993
67. Richard DE, Berra E, Pouyssegur J: Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Comm 266:718-722, 1999
68. Seimeister G, Weindel K, Mohrs K, et al: Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 56:2299-2301, 1996
69. Seizinger BR, Rouleau GA, Ozelius LJ, et al: Von Hippel-Lindau disease maps to the region of chomosome 3 associated with renal cell carcinoma. Nature 332:268-269, 1988
70. Semenza GL: Physiology meets biophysics: visualizing the interactions of hypoxia-inducible factor 1α with p300 and CBP. Proc Natl Acad Sci USA 99:11570-11572, 2002
71. Shuin T, Kondo K, Torigoe S, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852-2855, 1994
72. Stebbins CE, Kaelin WG Jr, Pavletich NP: Structure of the VHL-ElonginC-ElonginB Complex: implications for VHL tumor suppressor function. Science 284:455-461, 1999
73. Stratmann R, Krieg M, Haas R, et al: Putative control of angiogenesis in hemangiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropathol Exp Neurol 56:1242-1252, 1997
74. Sutter CH, Laughner E, Semenza GL: Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 97:4748-4753, 2000
75. Tanimoto K, Makino Y, Pereira T, et al: Mechanism of regulation of hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 19:4298-4309, 2000
76. Tibbs RE Jr, Bowles AP Jr, Raila FA, et al: Should endolymphatic sac tumors be considered part of the Von Hippel-Lindau complex? Pathology case report. Neurosurgery 410:848-855, 1997
77. Vincent KA, Shyu KG, Lou Y, et al: Angiogenesis is induced in a rabbit model of hindlimb ishemia by naked DNA encoding an HIF-1/VP16 hybrid transcription factor. Circulation 102: 2255-2261, 2000
78. Vortmeyer AO, Choo D, Pack SD, et al: Von Hippel-Lindau disease gene alterations associated with endolymphatic sac tumor. J Natl Cancer Inst 89:970-972, 1997
79. Vortmeyer AO, Huang SC, Koch CA, et al: Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Cancer Res 60:5963-5965, 2000
80. Wang GL, Jiang BH, Rue EA, et al: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510-5514, 1995
81. Weil RJ, Vortmeyer AO, Zhuang Z, et al: Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. Report of four cases. J Neurosurg 96:775-787, 2002
82. Wetli CV, Pardo V, Millard M, et al: Tumors of ceruminous glands. Cancer 29:1169-1178, 1972
83. Whaley JM, Naglich J, Gelbert L, et al: Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55:1092-1102, 1994
84. Yu F, White SB, Zhao Q, et al: Dynamic, site-specific interaction of hypoxia-inducible factor-1α with the von Hippel-Lindau tumor suppressor protein. Cancer Res 61:4136-4142, 2001
85. Yu F, White SB, Zhao Q, et al: HIF-1α binding to the VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 98:9630-9635, 2001
86. Zbar B, Kishida T, Chen F, et al: Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8:348-357, 1996
87. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor-1α in common human cancers and their metastases. Cancer Res 59:5830-5835, 1999
88. Zhuang Z, Gnarra JR, Dudley CF, et al: Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. Mod Pathol 9:838-842, 1996